A Randomized, Naturalistic, Parallel-Group Study for the Long-Term Treatment of Panic Disorder With Clonazepam or Paroxetine


Autoria(s): Nardi, Antonio E.; Freire, Rafael C.; Mochcovitch, Marina D.; Amrein, Roman; Levitan, Michelle N.; King, Anna L.; Valenca, Alexandre M.; Veras, Andre B.; Paes, Flavia; Sardinha, Aline; Nascimento, Isabella; Melo-Neto, Valfrido L. de; Dias, Gisele P.; O. e Silva, Adriana Cardoso de; Soares-Filho, Gastao L.; Costa, Rafael T. da; Mezzasalma, Marco A.; Carvalho, Marcele R. de; Cerqueira, Ana C. de; Hallak, Jaime E.; Crippa, Jose A.; Versiani, Marcio
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

11/09/2013

11/09/2013

2012

Resumo

This long-term extension of an 8-week randomized, naturalistic study in patients with panic disorder with or without agoraphobia compared the efficacy and safety of clonazepam (n = 47) and paroxetine (n = 37) over a 3-year total treatment duration. Target doses for all patients were 2 mg/d clonazepam and 40 mg/d paroxetine (both taken at bedtime). This study reports data from the long-term period (34 months), following the initial 8-week treatment phase. Thus, total treatment duration was 36 months. Patients with a good primary outcome during acute treatment continued monotherapy with clonazepam or paroxetine, but patients with partial primary treatment success were switched to the combination therapy. At initiation of the long-term study, the mean doses of clonazepam and paroxetine were 1.9 (SD, 0.30) and 38.4 (SD, 3.74) mg/d, respectively. These doses were maintained until month 36 (clonazepam 1.9 [ SD, 0.29] mg/d and paroxetine 38.2 [SD, 3.87] mg/d). Long-term treatment with clonazepam led to a small but significantly better Clinical Global Impression (CGI)-Improvement rating than treatment with paroxetine (mean difference: CGI-Severity scale -3.48 vs -3.24, respectively, P = 0.02; CGI-Improvement scale 1.06 vs 1.11, respectively, P = 0.04). Both treatments similarly reduced the number of panic attacks and severity of anxiety. Patients treated with clonazepam had significantly fewer adverse events than those treated with paroxetine (28.9% vs 70.6%, P < 0.001). The efficacy of clonazepam and paroxetine for the treatment of panic disorder was maintained over the long-term course. There was a significant advantage with clonazepam over paroxetine with respect to the frequency and nature of adverse events.

Brazilian Council for Scientific and Technological Development (CNPq)

Brazilian Council for Scientific and Technological Development (CNPq)

National Institute for Translational Medicine (INCT-TM)

National Institute for Translational Medicine (INCTTM)

Identificador

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, PHILADELPHIA, v. 32, n. 1, pp. 120-126, FEB, 2012

0271-0749

http://www.producao.usp.br/handle/BDPI/33257

10.1097/JCP.0b013e31823fe4bd

http://dx.doi.org/10.1097/JCP.0b013e31823fe4bd

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

PHILADELPHIA

Relação

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Direitos

closedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #CLONAZEPAM #PAROXETINE #PANIC DISORDER #PANIC ATTACKS #DOUBLE-BLIND #AGORAPHOBIA #DISCONTINUATION #EFFICACY #PLACEBO #BENZODIAZEPINES #PHARMACOTHERAPY #EPIDEMIOLOGY #WITHDRAWAL #ISSUES #PÂNICO #MANIFESTAÇÕES NEUROCOMPORTAMENTAIS #FARMACOTERAPIA #PHARMACOLOGY & PHARMACY #PSYCHIATRY
Tipo

article

original article

publishedVersion